<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675802</url>
  </required_header>
  <id_info>
    <org_study_id>Hysteroscopy</org_study_id>
    <nct_id>NCT03675802</nct_id>
  </id_info>
  <brief_title>Cervical Preparation in Hysteroscopy</brief_title>
  <official_title>Randomized Comparison of Vaginal Dinoprostone and Misoprostol for Cervical Ripening Before Diagnostic Hysteroscopy in Patients Who Have Undergone Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aljazeera Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aljazeera Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hysteroscopy was performed in the proliferativephase of the menstrual cycle.

      The patients were given generalintravenous anesthesia (propofol/fentanyl) after the vulvar
      and the vaginal area had been disinfected with a 7.5% Betadinesolution by the surgical nurse
      All operations were performed by the same surgeon to avoid possible discrepancies between
      different surgeons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Astandard rigid30 hysteroscope (Karl Storz bettocchi hysteroscope) with a 30° viewing
      angleand an outer sheath diameter 5.5 mm, inner sheath diameter 4.3 mm and scope diameter 2.9
      mmwas used in all procedures.

      A speculum was introduced into the vagina, and the uterine cervixwas visualized. Initially,
      the surgeon attempted to passthrough the cervical canal with the tool directly. When thatwas
      not possible or when the cervical canal was too rigid ortoo tight, the cervix was grasped
      with a tenaculum.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of women who will require cervical dilatation</measure>
    <time_frame>within an hour</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>GYN Disorders</condition>
  <arm_group>
    <arm_group_label>Arm number one ,misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm number 2 dinoprostone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <description>giving misoprostol to this group</description>
    <arm_group_label>Arm number one ,misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dinoprostone</intervention_name>
    <description>giving dinoprostine</description>
    <arm_group_label>Arm number 2 dinoprostone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients of reproductive age

          2. have undergone a cesarean section at least once

          3. an indication for diagnostic hysteroscopy for menstrualproblems or suspected
             intrauterine lesions (suchas uterine polyps and ﬁlling defects in the uterine cavity)
             by abnormal ﬁndings from hysterosalpingography,ultrasonography, or saline infusion
             sonography.

        Exclusion Criteria:

          1. Patients who delivered vaginally

          2. Had undergone any other transcervical or transabdominal uterine and cervical
             intervention other than cesareansection, such as loop electrosurgical procedures,
             cervical cryotherapy, cervical biopsies, and spontaneousabortions, previous dilation,
             and previous electiveabortions.

          3. Patients with cervical pathology,e.g. tears or polyps.

          4. The patients with a contraindicationto prostaglandins such as hypersensitivity,
             bronchial asthma, glaucoma, severeasthma, cardiac, liver or kidney diseases.

             -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women who needs diagnostic hysteroscopy</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mahmoud Alalfy, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud Alalfy</last_name>
    <phone>01002611058</phone>
    <email>mahmoudalalfy@ymail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Algazeerah</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Alalfy, master</last_name>
      <phone>+201002611058</phone>
      <email>mahmoudalalfy@ymail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ahmed Elgazzar, M.D</last_name>
      <phone>+201014005959</phone>
    </contact_backup>
    <investigator>
      <last_name>Mahmoud Alalfy, master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 16, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Diseases, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

